{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:01:16Z","timestamp":1794265276724,"version":"4.9.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kisu.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:13:49Z","timestamp":1784538829000},"page":"47-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["IgA nephropathy management: what does the future hold?"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1941","authenticated-orcid":false,"given":"Sydney C.W.","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather N.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2026.01.001_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib4","series-title":"The voice of the patient: externally led patient-focused drug development meeting on IgA nephropathy","year":"2020"},{"key":"10.1016\/j.kisu.2026.01.001_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11136-024-03813-x","article-title":"The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States","volume":"34","author":"Szklarzewicz","year":"2025","journal-title":"Qual Life Res"},{"key":"10.1016\/j.kisu.2026.01.001_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.kisu.2026.01.001_bib7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40271-021-00521-3","article-title":"Assessing patient preferences in rare diseases: direct preference elicitation in the rare chronic kidney disease, immunoglobulin A nephropathy","volume":"14","author":"Marsh","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.kisu.2026.01.001_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"10.1016\/j.kisu.2026.01.001_bib11","first-page":"S1","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","article-title":"Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines","volume":"318","author":"Woolf","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.kisu.2026.01.001_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.12809\/hkmj185083","article-title":"Pros and cons of clinical practice based on guidelines","volume":"24","author":"Chong","year":"2018","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.kisu.2026.01.001_bib14","first-page":"97","article-title":"Problems related to the application of guidelines in clinical practice: a critical analysis","volume":"52","author":"Geleris","year":"2011","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.kisu.2026.01.001_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13012-018-0763-4","article-title":"The advantages and limitations of guideline adaptation frameworks","volume":"13","author":"Wang","year":"2018","journal-title":"Implement Sci"},{"key":"10.1016\/j.kisu.2026.01.001_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/intqhc\/mzl007","article-title":"From outdated to updated, keeping clinical guidelines valid","volume":"18","author":"Clark","year":"2006","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.kisu.2026.01.001_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/kisup.2012.23","article-title":"Chapter 10: immunoglobulin A nephropathy","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.001_bib18","author":"Davis"},{"issue":"4S","key":"10.1016\/j.kisu.2026.01.001_bib19","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2026.01.001_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.001_bib23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.001_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2026.01.001_bib33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib34","author":"Calliditas Therapeutics"},{"key":"10.1016\/j.kisu.2026.01.001_bib35","author":"STADA Arzneimittel"},{"key":"10.1016\/j.kisu.2026.01.001_bib40","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ekir.2024.03.032","article-title":"The efficacy and safety of reduced-dose oral methylprednisolone in high-risk immunoglobulin A nephropathy","volume":"9","author":"Kim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.25259\/ijn_319_23","article-title":"State-of-art therapeutics in IgA nephropathy","volume":"34","author":"Mathur","year":"2024","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib45","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib50","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib51","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/jcm11102810","article-title":"New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies","volume":"11","author":"Maixnerova","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib52","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib57","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib59","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.0000000538","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1681\/ASN.0000000551","article-title":"From despair to promise: the dawn of novel treatment in IgA nephropathy","volume":"36","author":"Tang","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib65","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2026.01.001_bib66","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2026.01.001_bib67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/0886022X.2018.1532907","article-title":"The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China","volume":"40","author":"Fan","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.001_bib68","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2215\/CJN.14031119","article-title":"GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome","volume":"16","author":"Sanchez-Rodriguez","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib69","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.34067\/KID.0002972021","article-title":"The phenotypic difference of IgA nephropathy and its race\/gender-dependent molecular mechanisms","volume":"2","author":"Suzuki","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.kisu.2026.01.001_bib70","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.ekir.2022.03.016","article-title":"The International IgA Nephropathy Network prediction tool underestimates disease progression in Indian patients","volume":"7","author":"Bagchi","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib71","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/0886022X.2015.1128251","article-title":"The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial","volume":"38","author":"Yang","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.001_bib72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11255-016-1432-7","article-title":"Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis","volume":"49","author":"Duan","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2026.01.001_bib74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4772","article-title":"Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy","volume":"2","author":"Hirano","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kisu.2026.01.001_bib75","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.001_bib76","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/ndt\/gfq674","article-title":"A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy","volume":"26","author":"Wang","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.001_bib77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.ajkd.2014.06.036","article-title":"Tonsillectomy for IgA nephropathy: a meta-analysis","volume":"65","author":"Liu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.001_bib78","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib79","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib80","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.001_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kisu.2026.01.001_bib82","doi-asserted-by":"crossref","first-page":"452","DOI":"10.23876\/j.krcp.21.146","article-title":"A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy","volume":"41","author":"Han","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.kisu.2026.01.001_bib83","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib84","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.001_bib85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.001_bib86","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1080\/0886022X.2021.2000875","article-title":"Hydroxychloroquine in IgA nephropathy: a systematic review","volume":"43","author":"Stefan","year":"2021","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.001_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.001_bib88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kisu.2026.01.004","article-title":"The expanding role of biomarkers in the management of IgA nephropathy","volume":"15","author":"Jain","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.001_bib89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib90","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib91","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kisu.2026.01.001_bib92","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.001_bib93","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2021.10.007","article-title":"A novel scoring system based on Oxford classification indicating steroid therapy use for IgA nephropathy","volume":"7","author":"Itami","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib95","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ekir.2023.11.005","article-title":"Systematic review of the link between Oxford MEST-C classification and complement activation in IgA nephropathy","volume":"9","author":"Stefan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib96","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.001_bib97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.kisu.2026.01.002","article-title":"Management of IgA nephropathy and the expanding role of immunomodulation","volume":"15","author":"Canetta","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.001_bib98","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2026.01.001_bib99","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2020030349","article-title":"Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy","volume":"32","author":"Canney","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib101","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.001_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.001_bib103","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.001_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089783","article-title":"Rate of decline in kidney function with age: a systematic review","volume":"14","author":"Guppy","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.kisu.2026.01.001_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129036","article-title":"Longitudinal study of the decline in renal function in healthy subjects","volume":"10","author":"Baba","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.001_bib106","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib107","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.ekir.2023.06.016","article-title":"Clinicopathological characteristics of adult IgA nephropathy in the United States","volume":"8","author":"Caster","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.001_bib108","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000516911","article-title":"From proteinuria to fibrosis: an update on pathophysiology and treatment options","volume":"46","author":"Sharma","year":"2021","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kisu.2026.01.001_bib109","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","article-title":"The incidence and prevalence of IgA nephropathy in Europe","volume":"38","author":"Willey","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.001_bib110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10157-015-1129-8","article-title":"Epidemiological survey and clinical investigation of pediatric IgA nephropathy","volume":"20","author":"Shibano","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib112","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.001_bib113","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CEOR.S389456","article-title":"Cost-effectiveness analysis of Nefecon versus best supportive care for people with immunoglobulin A nephropathy (IgAN) in the United States","volume":"15","author":"Ramjee","year":"2023","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:05:51Z","timestamp":1785974751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171626000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2157171626000018"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.001","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgA nephropathy management: what does the future hold?","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2025.12.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}